Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept….
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept….
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept….
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…
—Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated…
—Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated…
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…
– Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related…